Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$8.29 USD
+0.03 (0.36%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $8.28 -0.01 (-0.12%) 5:56 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Maravai LifeSciences Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 289 | 883 | 799 | 284 | 143 |
Cost Of Goods | 149 | 169 | 141 | 80 | 67 |
Gross Profit | 140 | 714 | 659 | 204 | 76 |
Selling & Adminstrative & Depr. & Amort Expenses | 172 | 140 | 104 | 85 | 52 |
Income After Depreciation & Amortization | -32 | 574 | 555 | 120 | 24 |
Non-Operating Income | 695 | -2 | 6 | -7 | 0 |
Interest Expense | 46 | 20 | 30 | 31 | 30 |
Pretax Income | 618 | 551 | 531 | 82 | -6 |
Income Taxes | 756 | 61 | 62 | 3 | -1 |
Minority Interest | -19 | 270 | 287 | -10 | -1 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -138 | 491 | 469 | 79 | -5 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -119 | 220 | 182 | 89 | -4 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 20 | 615 | 582 | 148 | 50 |
Depreciation & Amortization (Cash Flow) | 52 | 41 | 27 | 28 | 26 |
Income After Depreciation & Amortization | -32 | 574 | 555 | 120 | 24 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 131.92 | 255.32 | 257.80 | 28.91 | NA |
Diluted EPS Before Non-Recurring Items | -0.22 | 1.80 | 1.60 | 1.70 | NA |
Diluted Net EPS (GAAP) | -0.90 | 1.67 | 1.56 | 2.36 | -0.03 |
Fiscal Year end for Maravai LifeSciences Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | 73.40 | 64.18 | 74.14 | 66.87 |
Cost Of Goods | NA | 38.27 | 38.34 | 35.11 | 36.69 |
Gross Profit | NA | 35.13 | 25.84 | 39.03 | 30.18 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 44.64 | 44.70 | 39.71 | 45.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -9.51 | -18.86 | -0.68 | -15.42 |
Non-Operating Income | NA | 4.52 | 7.32 | 678.74 | 6.49 |
Interest Expense | NA | 11.94 | 10.86 | 15.40 | 11.64 |
Pretax Income | NA | -16.93 | -22.41 | 656.19 | -20.56 |
Income Taxes | NA | -2.44 | 0.27 | 766.17 | -5.46 |
Minority Interest | NA | -6.91 | -10.60 | -4.02 | -8.64 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -14.49 | -22.68 | -109.98 | -15.10 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -7.59 | -12.08 | -105.96 | -6.46 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 135.84 | 132.33 | 132.14 | 131.93 |
Diluted EPS Before Non-Recurring Items | NA | -0.08 | -0.11 | -0.05 | -0.02 |
Diluted Net EPS (GAAP) | NA | -0.05 | -0.09 | -0.80 | -0.05 |